Elan Corporation PLC And Biogen Idec, Inc. (Massachusetts) Submit Supplemental Biologics License Application To The FDA For The Approval Of TYSABRI(R) As A Treatment For Crohn’s Disease

DUBLIN, Ireland & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval to market TYSABRI® (natalizumab) in the U.S. as a treatment for patients with moderately to severely active Crohn's disease (CD).